HighTower Advisors’s Quest Diagnostics DGX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$14.3M Buy
67,692
+7,678
+13% +$1.51M 0.01% 779
2026
Q1
$11.8M Buy
60,014
+18,667
+45% +$3.63M 0.01% 811
2025
Q4
$7.17M Buy
41,347
+597
+1% +$109K 0.01% 1008
2025
Q3
$7.77M Buy
40,750
+1,814
+5% +$322K 0.01% 954
2025
Q2
$6.99M Buy
38,936
+10,000
+35% +$1.74M 0.01% 956
2025
Q1
$4.9M Buy
28,936
+526
+2% +$86.4K 0.01% 1060
2024
Q4
$4.29M Sell
28,410
-34
-0.1% -$5.29K 0.01% 1113
2024
Q3
$4.42M Buy
28,444
+493
+2% +$73.6K 0.01% 1085
2024
Q2
$3.83M Buy
27,951
+262
+0.9% +$35.9K 0.01% 1116
2024
Q1
$3.69M Sell
27,689
-2,829
-9% -$367K 0.01% 1105
2023
Q4
$4.22M Sell
30,518
-11
-0% -$1.45K 0.01% 1059
2023
Q3
$3.72M Sell
30,529
-7,678
-20% -$1.02M 0.01% 1058
2023
Q2
$5.38M Buy
38,207
+3,069
+9% +$423K 0.01% 871
2023
Q1
$4.98M Sell
35,138
-3,691
-10% -$528K 0.01% 861
2022
Q4
$6.09M Buy
38,829
+818
+2% +$118K 0.01% 777
2022
Q3
$4.67M Sell
38,011
-507
-1% -$66.8K 0.01% 833
2022
Q2
$5.12M Sell
38,518
-36,293
-49% -$4.95M 0.01% 807
2022
Q1
$10.2M Sell
74,811
-5,386
-7% -$751K 0.02% 618
2021
Q4
$13.9M Buy
80,197
+363
+0.5% +$55.2K 0.03% 492
2021
Q3
$11.6M Buy
79,834
+14,718
+23% +$2.15M 0.03% 486
2021
Q2
$8.59M Buy
65,116
+418
+0.6% +$54.7K 0.02% 578
2021
Q1
$8.3M Buy
64,698
+10,854
+20% +$1.34M 0.03% 548
2020
Q4
$6.42M Buy
53,844
+4,050
+8% +$494K 0.03% 509
2020
Q3
$5.7M Buy
49,794
+21,792
+78% +$2.57M 0.03% 511
2020
Q2
$3.19M Buy
28,002
+12,560
+81% +$1.33M 0.02% 655
2020
Q1
$1.24M Buy
15,442
+4,139
+37% +$429K 0.01% 916
2019
Q4
$1.21M Sell
11,303
-1,085
-9% -$113K 0.01% 1060
2019
Q3
$1.33M Sell
12,388
-1,382
-10% -$142K 0.01% 1048
2019
Q2
$1.4M Sell
13,770
-8,368
-38% -$804K 0.01% 1049
2019
Q1
$2M Sell
22,138
-2,606
-11% -$226K 0.01% 855
2018
Q4
$2.05M Buy
24,744
+4,222
+21% +$396K 0.02% 759
2018
Q3
$2.22M Buy
20,522
+2,312
+13% +$254K 0.02% 797
2018
Q2
$2.01M Buy
18,210
+4,516
+33% +$470K 0.02% 848
2018
Q1
$1.38M Buy
13,694
+1,003
+8% +$103K 0.01% 946
2017
Q4
$1.25M Sell
12,691
-536
-4% -$50.8K 0.01% 1007
2017
Q3
$1.24M Sell
13,227
-286
-2% -$30.4K 0.01% 992
2017
Q2
$1.5M Buy
13,513
+1,201
+10% +$127K 0.01% 911
2017
Q1
$1.21M Sell
12,312
-1,531
-11% -$146K 0.01% 950
2016
Q4
$1.27M Buy
13,843
+1,498
+12% +$129K 0.01% 875
2016
Q3
$1.04M Buy
12,345
+1,812
+17% +$152K 0.01% 894
2016
Q2
$856K Sell
10,533
-6,510
-38% -$496K 0.01% 951
2016
Q1
$1.22M Sell
17,043
-1,570
-8% -$105K ﹤0.01% 933
2015
Q4
$1.33M Buy
18,613
+10,181
+121% +$684K 0.02% 820
2015
Q3
$517K Sell
8,432
-8,214
-49% -$574K 0.01% 1185
2015
Q2
$1.21M Buy
16,646
+6,714
+68% +$496K 0.02% 689
2015
Q1
$764K Sell
9,932
-425
-4% -$30.4K 0.01% 913
2014
Q4
$695K Sell
10,357
-29,234
-74% -$1.84M 0.01% 941
2014
Q3
$2.4M Sell
39,591
-6,218
-14% -$383K 0.04% 484
2014
Q2
$2.69M Buy
45,809
+42,344
+1,222% +$2.48M 0.05% 468
2014
Q1
$201K Sell
3,465
-36,919
-91% -$1.98M ﹤0.01% 1315
2013
Q4
$2.16M Buy
40,384
+31,308
+345% +$1.86M 0.04% 438
2013
Q3
$561K Sell
9,076
-180
-2% -$10.8K 0.01% 805
2013
Q2
$561K Buy
+9,256
New +$551K 0.02% 765

Other funds holding DGX

HighTower Advisors's DGX Position: Q2 2026 in Review

HighTower Advisors increased its Quest Diagnostics (DGX) stake by 13% in Q2 2026, buying an estimated $1.51M and bringing the position to 67,692 shares worth $14.3M. The position accounts for 0.01% of the portfolio, ranked #779.

HighTower Advisors first reported a position in DGX in Q2 2013 and has held it in 53 quarters since. 1,100 funds tracked by Wall St. Rank hold DGX as of Q2 2026.

  • HighTower Advisors held 67,692 shares of Quest Diagnostics worth $14.3M as of Q2 2026.
  • HighTower Advisors bought 7,678 Quest Diagnostics shares in Q2 2026, an estimated $1.51M.
  • Quest Diagnostics made up 0.01% of HighTower Advisors's portfolio in Q2 2026, its #779 holding.
  • HighTower Advisors first reported a position in Quest Diagnostics in Q2 2013 and has held it in 53 quarters since.
  • 1,100 funds tracked by Wall St. Rank held Quest Diagnostics as of Q2 2026.

Based on HighTower Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.